Summit's November 14 decision: what the FDA is weighing

Haverhill Financial Research · News · October 11, 2026

The FDA is due to decide by November 14 whether to approve Summit Therapeutics' ivonescimab, given with chemotherapy, for patients with EGFR-mutated non-small cell lung cancer whose disease has progressed after EGFR-targeted pills. It would be the drug's first approval outside China, where its developer Akeso already sells it.

The application rests on HARMONi, a Phase 3 trial with a clear win on one measure and a near-miss on another. How the FDA weighs the two is the whole story.

Progression-free survival tells you whether a drug holds a tumor back; overall survival tells you whether patients live longer. Regulators accept progression-free survival as a basis for approval in many cancers, but when a survival result points the right way without reaching significance, the agency has to decide how much weight to give it.

Summit's case is that a hazard ratio of 0.52 is a large effect and that the survival trend supports it. The open questions are how the FDA reads the survival data and whether it is satisfied that results in Western patients, about 38% of those enrolled, match those in the trial as a whole. Earlier ivonescimab trials ran mainly in China.

Approval would give Summit its first commercial product and a US launch in a defined second-line lung cancer group. A complete response letter would mean the FDA wants more, most likely more survival data or more evidence in Western patients. An extension of three months is possible if Summit submits significant new information during the review, as happened to Capricor and Praxis this year. The FDA can also act before the date.

The label wording if it is approved, especially whether survival data appears in it; any comment from Summit on its larger trials in first-line lung cancer, which matter more to the company's long-term value than this indication; and how Summit plans to fund a launch.

This is a genuinely uncertain decision. The progression result is strong enough to support approval on its own in many cancers; the survival result is the reason it is not a formality. Summit is not a company we cover with a rating, and this is not a call on the outcome.

Summit Therapeutics press releases on HARMONi results and on FDA acceptance of the biologics license application, and Summit's fourth-quarter 2025 results and subsequent quarterly reports.

Disclosures. Haverhill Financial Research is a publisher of general financial commentary. This article is not personalized investment advice and does not consider any reader's financial situation; readers should do their own research. Nothing here is a recommendation to buy or sell any security. Company figures and guidance can change. The author of this post does not hold positions in the companies named. Data as of October 11, 2026.